Cardiac screening
Ask whether medical history, medication review, and cardiac assessment are completed before treatment, how concerning findings are handled, and whether the decision to proceed is documented.
Canada-based provider questions
Clinic Comparison Guide
Comparing ibogaine providers calls for more than a compelling website or a broad promise. This guide focuses on the safety, oversight, and documentation questions that make a provider easier to assess. For wider background on ibogaine and psychedelic drug context, start with the substance itself before weighing any program.
A careful starting point
Ask what can be checked.
Ibogaine is associated with potentially serious cardiac and medication-interaction risks. A comparison should therefore begin with whether a provider can clearly explain screening, monitoring, escalation, and follow-up—not with testimonials or broad statements about outcomes. A plain-language overview of how ibogaine works may help identify the questions a program should be prepared to answer.
In Canada, regulatory status and professional scope matter alongside a provider’s own policies. Health Canada’s Drug Product Database is a useful official place to distinguish marketed drug products from unsupported assumptions about availability. This page is designed as an independent comparison aid for addiction-treatment decisions, and the broader safety-focused assessment approach can help keep the conversation anchored in verifiable details.
Three priorities
The standard is observable medical readiness.
A provider need not answer every question with certainty, but it should be able to describe who is responsible, what is documented, and what happens when a risk is identified.
Continuous oversight
Ask who is present during treatment, whether a licensed prescriber or physician has a defined role, and how vital signs and changes in condition are monitored.
Escalation planning
Ask what emergency equipment, medications, transfer arrangements, and response procedures are available—and whether the provider can explain them without evasion.
Medical oversight
Treat transparency as evidence.
Peer-reviewed literature has described safety concerns around ibogaine, including cardiac effects; the PubMed record of ibogaine cardiac safety research gives readers a way to see how that concern is discussed in the medical literature. It does not establish that a particular provider is safe or effective.
A provider’s willingness to identify limits, exclusions, and transfer procedures is more useful than an assurance that risk has been eliminated.
Ask whether medication sourcing is traceable through lawful pharmacy standards and whether the program can explain its informed-consent process before payment or travel commitments. Comparison pages for Canadian ibogaine treatment centres can surface options, but they should not substitute for direct verification. The same caution applies when comparing ibogaine HCl information with the actual product, documentation, and oversight a provider describes.
Reusable framework
A record of questions, not a promise of outcomes.
Use this table to compare written or verbal answers across providers. Record what was supplied, what remains unclear, and whether the answer can be independently verified. A refusal to discuss safety procedures is itself useful information.
| Area to verify | Question to ask | What a usable answer should clarify |
|---|---|---|
| Pre-treatment assessment | What screening occurs before treatment, including medication and cardiac review? | Who reviews the information, what may exclude participation, and how findings affect the plan. |
| Responsible clinician | Who holds clinical responsibility, and what is that person’s role during treatment? | Whether a licensed physician or prescriber is involved, available, and identifiable through appropriate provincial channels. |
| Monitoring | What monitoring is used during and after administration, and who interprets it? | The method, timing, trained personnel, and response to concerning changes. |
| Emergency response | What is the emergency protocol, and how would transfer to higher-acuity care occur? | Available equipment, trained responders, local transfer arrangements, and decision-making authority. |
| Medication sourcing | How is the medication obtained, stored, documented, and checked? | Traceability, pharmacy involvement where applicable, and a clear explanation of product handling. |
| Consent and follow-up | When is informed consent provided, and what medical follow-up is offered after treatment? | Time to review risks, alternatives, and limits; plus a defined plan for follow-up and urgent concerns. |
Before deciding
Keep comparison notes specific.
A checklist is most useful when it separates what a provider says from what can be confirmed. Families comparing support for trauma-related concerns may encounter claims about ibogaine for PTSD treatment or ibogaine therapy for PTSD; those claims should not displace the core questions about suitability, medical risk, consent, and continuity of care.
- Request screening, consent, monitoring, and follow-up policies in writing where possible.
- Note the date of each answer and the role of the person giving it.
- Ask what would make the provider decline or postpone treatment.
- Compare emergency plans with the actual location and available level of care.
- Discuss current medications and medical history with an appropriately qualified clinician who knows your circumstances.
A measured next step
Choose the provider that can withstand careful questions.
Programs described as ibogaine detox centres or associated with an ibogaine clinic in Tijuana may use different settings and practices. The comparison standard remains the same: clear screening, accountable oversight, credible emergency planning, documented consent, and a realistic follow-up plan. For the purpose and boundaries behind this resource, see Ardent Sieve’s independent approach.